Cargando…

Allele-specific disparity in breast cancer

BACKGROUND: In a cancer cell the number of copies of a locus may vary due to amplification and deletion and these variations are denoted as copy number alterations (CNAs). We focus on the disparity of CNAs in tumour samples, which were compared to those in blood in order to identify the directional...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaveh, Fatemeh, Edvardsen, Hege, Børresen-Dale, Anne-Lise, N Kristensen, Vessela, Solvang, Hiroko K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337547/
https://www.ncbi.nlm.nih.gov/pubmed/22188678
http://dx.doi.org/10.1186/1755-8794-4-85
_version_ 1782231096314822656
author Kaveh, Fatemeh
Edvardsen, Hege
Børresen-Dale, Anne-Lise
N Kristensen, Vessela
Solvang, Hiroko K
author_facet Kaveh, Fatemeh
Edvardsen, Hege
Børresen-Dale, Anne-Lise
N Kristensen, Vessela
Solvang, Hiroko K
author_sort Kaveh, Fatemeh
collection PubMed
description BACKGROUND: In a cancer cell the number of copies of a locus may vary due to amplification and deletion and these variations are denoted as copy number alterations (CNAs). We focus on the disparity of CNAs in tumour samples, which were compared to those in blood in order to identify the directional loss of heterozygosity. METHODS: We propose a numerical algorithm and apply it to data from the Illumina 109K-SNP array on 112 samples from breast cancer patients. B-allele frequency (BAF) and log R ratio (LRR) of Illumina were used to estimate Euclidian distances. For each locus, we compared genotypes in blood and tumour for subset of samples being heterozygous in blood. We identified loci showing preferential disparity from heterozygous toward either the A/B-allele homozygous (allelic disparity). The chi-squared and Cochran-Armitage trend tests were used to examine whether there is an association between high levels of disparity in single nucleotide polymorphisms (SNPs) and molecular, clinical and tumour-related parameters. To identify pathways and network functions over-represented within the resulting gene sets, we used Ingenuity Pathway Analysis (IPA). RESULTS: To identify loci with a high level of disparity, we selected SNPs 1) with a substantial degree of disparity and 2) with substantial frequency (at least 50% of the samples heterozygous for the respective locus). We report the overall difference in disparity in high-grade tumours compared to low-grade tumours (p-value < 0.001) and significant associations between disparity in multiple single loci and clinical parameters. The most significantly associated network functions within the genes represented in the loci of disparity were identified, including lipid metabolism, small-molecule biochemistry, and nervous system development and function. No evidence for over-representation of directional disparity in a list of stem cell genes was obtained, however genes appeared to be more often altered by deletion than by amplification. CONCLUSIONS: Our data suggest that directional loss and amplification exist in breast cancer. These are highly associated with grade, which may indicate that they are enforced with increasing number of cell divisions. Whether there is selective pressure for some loci to be preferentially amplified or deleted remains to be confirmed.
format Online
Article
Text
id pubmed-3337547
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33375472012-04-27 Allele-specific disparity in breast cancer Kaveh, Fatemeh Edvardsen, Hege Børresen-Dale, Anne-Lise N Kristensen, Vessela Solvang, Hiroko K BMC Med Genomics Research Article BACKGROUND: In a cancer cell the number of copies of a locus may vary due to amplification and deletion and these variations are denoted as copy number alterations (CNAs). We focus on the disparity of CNAs in tumour samples, which were compared to those in blood in order to identify the directional loss of heterozygosity. METHODS: We propose a numerical algorithm and apply it to data from the Illumina 109K-SNP array on 112 samples from breast cancer patients. B-allele frequency (BAF) and log R ratio (LRR) of Illumina were used to estimate Euclidian distances. For each locus, we compared genotypes in blood and tumour for subset of samples being heterozygous in blood. We identified loci showing preferential disparity from heterozygous toward either the A/B-allele homozygous (allelic disparity). The chi-squared and Cochran-Armitage trend tests were used to examine whether there is an association between high levels of disparity in single nucleotide polymorphisms (SNPs) and molecular, clinical and tumour-related parameters. To identify pathways and network functions over-represented within the resulting gene sets, we used Ingenuity Pathway Analysis (IPA). RESULTS: To identify loci with a high level of disparity, we selected SNPs 1) with a substantial degree of disparity and 2) with substantial frequency (at least 50% of the samples heterozygous for the respective locus). We report the overall difference in disparity in high-grade tumours compared to low-grade tumours (p-value < 0.001) and significant associations between disparity in multiple single loci and clinical parameters. The most significantly associated network functions within the genes represented in the loci of disparity were identified, including lipid metabolism, small-molecule biochemistry, and nervous system development and function. No evidence for over-representation of directional disparity in a list of stem cell genes was obtained, however genes appeared to be more often altered by deletion than by amplification. CONCLUSIONS: Our data suggest that directional loss and amplification exist in breast cancer. These are highly associated with grade, which may indicate that they are enforced with increasing number of cell divisions. Whether there is selective pressure for some loci to be preferentially amplified or deleted remains to be confirmed. BioMed Central 2011-12-21 /pmc/articles/PMC3337547/ /pubmed/22188678 http://dx.doi.org/10.1186/1755-8794-4-85 Text en Copyright ©2011 2011 Kaveh et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kaveh, Fatemeh
Edvardsen, Hege
Børresen-Dale, Anne-Lise
N Kristensen, Vessela
Solvang, Hiroko K
Allele-specific disparity in breast cancer
title Allele-specific disparity in breast cancer
title_full Allele-specific disparity in breast cancer
title_fullStr Allele-specific disparity in breast cancer
title_full_unstemmed Allele-specific disparity in breast cancer
title_short Allele-specific disparity in breast cancer
title_sort allele-specific disparity in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337547/
https://www.ncbi.nlm.nih.gov/pubmed/22188678
http://dx.doi.org/10.1186/1755-8794-4-85
work_keys_str_mv AT kavehfatemeh allelespecificdisparityinbreastcancer
AT edvardsenhege allelespecificdisparityinbreastcancer
AT børresendaleannelise allelespecificdisparityinbreastcancer
AT nkristensenvessela allelespecificdisparityinbreastcancer
AT solvanghirokok allelespecificdisparityinbreastcancer